Literature DB >> 311683

A clinical and pharmacological study of high-dose methotrexate with minimal leucovorin rescue.

R G Stoller, H G Kaplan, F J Cummings, P Calabresi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 311683

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  11 in total

1.  Alleviation by leucovorin of the dose-limiting toxicity of edatrexate: potential for improved therapeutic efficacy.

Authors:  J S Lee; W K Murphy; M H Shirinian; A Pang; W K Hong
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  Pharmacokinetics of (-)-folinic acid after oral and intravenous administration of the racemate.

Authors:  P O Greiner; J Zittoun; J Marquet; J M Cheron
Journal:  Br J Clin Pharmacol       Date:  1989-09       Impact factor: 4.335

Review 3.  The practical benefits of pharmacokinetics in the use of antineoplastic agents.

Authors:  C Erlichman; R C Donehower; B A Chabner
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

4.  Pharmacokinetics of methotrexate administered via the hepatic artery.

Authors:  R J Ignoffo; S Oie; M A Friedman
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

5.  Early, empiric high-dose leucovorin rescue in lymphoma patients treated with sequential doses of high-dose methotrexate.

Authors:  Jason N Barreto; Kristen T Peterson; Erin F Barreto; Kristin C Mara; Ross A Dierkhising; Nelson Leung; Thomas E Witzig; Carrie A Thompson
Journal:  Support Care Cancer       Date:  2021-03-04       Impact factor: 3.603

Review 6.  Mechanisms, Management and Prevention of Pemetrexed-Related Toxicity.

Authors:  Nikki de Rouw; Berber Piet; Hieronymus J Derijks; Michel M van den Heuvel; Rob Ter Heine
Journal:  Drug Saf       Date:  2021-11-06       Impact factor: 5.606

7.  Extracorporeal Treatment for Methotrexate Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.

Authors:  Marc Ghannoum; Darren M Roberts; David S Goldfarb; Jesper Heldrup; Kurt Anseeuw; Tais F Galvao; Thomas D Nolin; Robert S Hoffman; Valery Lavergne; Paul Meyers; Sophie Gosselin; Tudor Botnaru; Karine Mardini; David M Wood
Journal:  Clin J Am Soc Nephrol       Date:  2022-03-02       Impact factor: 10.614

8.  Clinical pharmacokinetics of 6-hour infusion of high-dose methotrexate. Preliminary trial of monitoring high infusion doses.

Authors:  M Luyckx; J L Cazin; C Brunet; P Gosselin; M C Demaille
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

9.  The effect of timing of a single injection on the toxicity of methotrexate in the rat.

Authors:  J English; G W Aherne; V Marks
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

10.  Critical factors for the reversal of methotrexate cytotoxicity by folinic acid.

Authors:  S Bernard; M C Etienne; J L Fischel; P Formento; G Milano
Journal:  Br J Cancer       Date:  1991-02       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.